LA
REGN icon

Legacy Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Legacy Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-435
Closed -$276K – 322
2025
Q1 		$276K Buy
435
+73
+20% +$50.2K 0.03% 349
2024
Q4 		$258K Buy
362
+64
+21% +$53.7K 0.03% 335
2024
Q3 		$313K Buy
298
+70
+31% +$77.9K 0.03% 293
2024
Q2 		$240K Buy
228
+20
+10% +$19.4K 0.03% 287
2024
Q1 		$200K Buy
+208
New +$198K 0.03% 304
2017
Q4 		– Sell
-20
Closed -$8K – 414
2017
Q3 		$8K Buy
+20
New +$9.52K 0.01% 240

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legacy Advisors's REGN Position: Q2 2025 in Review

Legacy Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 435 shares — an estimated $276K sold.

Legacy Advisors first reported a position in REGN in Q3 2017 and held it in 6 quarters. The position peaked at $313K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Legacy Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legacy Advisors sold 435 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $276K.
  • Legacy Advisors first reported a position in Regeneron Pharmaceuticals in Q3 2017 and held it in 6 quarters.
  • Legacy Advisors's Regeneron Pharmaceuticals position peaked at $313K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Legacy Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.